REGN

Business Context and Reporting Period

Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Regeneron is a biopharmaceutical company focused on discovering and developing products for serious medical conditions. The company has no approved commercial products and has not generated profits from product sales since inception. Its primary clinical programs include the VEGF Trap (oncology and eye diseases) and the IL-1 Trap (inflammatory diseases). The company operates two segments: Research & Development and Contract Manufacturing.

Key Financial Metrics

Note: 2005 results include $19.9 million in non-cash stock-based compensation expense due to the adoption of SFAS 123. Excluding this expense, the pro forma net loss for 2005 was $75.5 million.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 62% from $174.0 million in 2004 to $66.2 million in 2005. This was primarily due to the expiration of the collaboration with The Procter & Gamble Company in June 2005 and the cessation of revenue recognition from the Novartis collaboration (which ended in 2004).
• Profitability Shift: The company swung from a net income of $41.7 million in 2004 to a net loss of $95.4 million in 2005. The 2004 income was bolstered by a $42.75 million payment from Novartis and a $17.8 million loan forgiveness, neither of which occurred in 2005.
• Expense Increase: Operating expenses increased to $190.6 million in 2005 from $168.4 million in 2004. This increase was driven by higher R&D costs for clinical trials and the new accounting standard for stock-based compensation ($19.9 million expense).
• Collaboration Expansion: In December 2005, Regeneron amended its agreement with sanofi-aventis to include Japan in the collaboration territory, securing a $25.0 million up-front payment (received in January 2006).

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management expects to incur substantial losses over the next several years as clinical development continues.
• Capital resources are projected to meet operating needs through at least mid-2008.
• 2006 R&D expenses are expected to increase 5-10% compared to 2005.
• Headcount is expected to decrease to approximately 600 in 2006 following workforce reductions announced in late 2005.

Key Risks and Contingencies:

• Product Development Risk: No products have been approved for sale. Success depends on clinical trial results and regulatory approvals, which are uncertain.
• Collaboration Dependence: The company relies heavily on sanofi-aventis for funding the VEGF Trap oncology program. Sanofi-aventis can terminate the agreement with 12 months' notice.
• Revenue Concentration: Revenue is derived primarily from collaborations (sanofi-aventis, Merck) and contract manufacturing. The expiration of the Merck manufacturing agreement in October 2006 poses a future revenue risk.
• Debt Obligations: The company has $200 million in convertible senior subordinated notes maturing in 2008 with semi-annual interest payments.
• Competition: Significant competition exists in oncology (e.g., Genentech's Avastin) and eye diseases (e.g., Eyetech/Pfizer's Macugen).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $316.7 million cash position to fund operations through mid-2008 without additional financing.
• Collaboration Terms: Review the specific milestones and reimbursement obligations under the sanofi-aventis agreement, particularly the 50% reimbursement of development costs if the collaboration becomes profitable.
• Merck Agreement Expiration: Assess the impact of the Merck contract manufacturing agreement expiring in October 2006 on future revenue streams.
• Clinical Trial Progress: Monitor upcoming Phase 2 results for VEGF Trap in oncology and VEGF Trap-Eye in wet AMD, as well as the pivotal study for IL-1 Trap in CAPS.
• Stock-Based Compensation: Understand the impact of SFAS 123R adoption in 2006 on future reported earnings.